Igantet

Human Tetanus Immunoglobulin, the active ingredient in Igantet, is a immunoglobulin (tetanus immune globulin) presented as an injection for intramuscular use. It provides passive immunity for prevention and treatment of tetanus in individuals with insufficient immunization or active disease.

GNH USA supplies Igantet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Igantet (Human Tetanus Immunoglobulin) belongs to the tetanus immune globulin class and provides passive protection against tetanus toxin.

Prevention of tetanus: Provides immediate passive immunity for individuals lacking adequate tetanus vaccination. Treatment of tetanus: Supplies neutralizing antibodies to reduce toxin activity in patients with clinical tetanus. Wound management prophylaxis: Administered after high‑risk injuries when vaccination status is uncertain to prevent tetanus infection.

Igantet may cause adverse reactions related to its immunoglobulin content and the injection process.

Common Side Effects: - Injection site pain: mild discomfort at the site of intramuscular administration. - Redness or swelling: localized erythema or edema around the injection area. - Fever: transient low‑grade temperature elevation. - Headache: mild to moderate headache occurring shortly after dosing.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction that may include difficulty breathing, hypotension, or rash. - Serum sickness: immune complex–mediated reaction presenting with fever, rash, arthralgia. - Urticaria: widespread hives indicating hypersensitivity. - Hemolysis: rare destruction of red blood cells leading to anemia.

Before using Igantet, consider the following precautions to ensure safe administration.

Assess immunization history: Verify the patient’s tetanus vaccination status and need for passive immunization. Known hypersensitivity: Do not administer to individuals with documented allergy to human immunoglobulins or any product component. IgA deficiency: Use with caution in patients with selective IgA deficiency due to risk of anaphylactic reactions. Concurrent vaccines: Delay active tetanus vaccination for at least 4 weeks after Igantet to avoid interference with antibody response. Pregnancy and lactation: Weigh potential benefits against unknown risks; consult obstetric guidance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Igantet can interact with other agents that affect immune response or vaccine efficacy.

Major Interactions (Avoid): - Simultaneous tetanus toxoid vaccine: may reduce the immunogenicity of the active vaccine. - IgA‑deficient plasma products: increased risk of severe allergic reactions.

Moderate Interactions (Monitor Closely): - Live vaccines administered within 4 weeks: possible diminished effectiveness; monitor immune status. - Immunosuppressive therapy: may alter the duration of passive protection; assess antibody levels if needed. - Anticoagulants: intramuscular injection may increase bleeding risk; apply pressure after administration.